Best of UEG Week 2026 - Endoscopy with Giuseppe Vanella
What stood out in endoscopy at UEG Week 2026? Egle Dieninyte asks Giuseppe Vanella, interventional endoscopist from Milan, for his highlights from Barcelona. His verdict: the most important studies asked simple questions, and the field is shifting from technical feasibility to clinical impact.
They discuss COBRA, the Dutch randomised trial in the opening plenary, in which one day of antibiotics after adequate biliary drainage in acute cholangitis gave similar clinical cure to a full course with fewer adverse events, in a selected population. Giuseppe singles out TESLA as the most challenging evidence: primary percutaneous suprapapillary stenting of malignant hilar strictures had fewer adverse events and much less cholangitis than ERCP. He cautions that it compared an optimised radiological strategy with heterogeneous endoscopic practice, but argues that endoscopy must now standardise and match those outcomes, including through EUS-guided transmural drainage. Two Italian randomised trials of underwater versus gas-assisted colorectal ESD follow, with better or comparable R0 resection, faster dissection and less bleeding. The conversation closes on the risks of rapid adoption of interventional EUS outside expert centres, and the shared responsibility of societies and researchers to set training standards and report complications, long-term and patient-reported outcomes.
Research and further reading
Discussed in the episode (UEG Week 2026 presentations, recordings on Gutflix):
- One day of antibiotic treatment is non-inferior to 4-7 days in patients with acute cholangitis after adequate biliary drainage: a multi-centre randomised controlled trial (COBRA). Anouk Overdevest. UEG Week 2026, abstract OP001, opening plenary.
- Primary percutaneous stenting versus endoscopic drainage for unresectable malignant hilar biliary obstruction: a multicenter randomized controlled trial, the TESLA RCT. Bas Groot Koerkamp. UEG Week 2026, late-breaking abstract LB03.
- Water-assisted versus standard ESD for large nonpedunculated colorectal polyps: a randomized controlled trial (the WAVE-ESD study). Ludovico Alfarone. UEG Week 2026, late-breaking abstract LB04.
- Underwater versus conventional endoscopic submucosal dissection for colorectal neoplasia: a multicenter, randomised controlled trial. Arianna Andreozzi. UEG Week 2026, abstract OP008.
Trial protocols (published background to the trials discussed):
- Antibiotic treatment for 1 day versus 4-7 days in patients with acute cholangitis after adequate endoscopic biliary drainage (COBRA): study protocol for a randomized controlled trial. Overdevest AG et al. Trials, 2026.
- Primary percutaneous stenting above the ampulla versus endoscopic drainage for unresectable malignant hilar biliary obstruction (TESLA RCT): study protocol for a multicenter randomized controlled trial. Rousian M et al. BMC Cancer, 2025.
Additional further reading (not mentioned by name in the episode):
- Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated October 2017. Dumonceau JM et al. Endoscopy, 2018. ESGE guidance on biliary stenting, including malignant hilar obstruction.
- Therapeutic endoscopic ultrasound: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. van der Merwe SW et al. Endoscopy, 2022. ESGE recommendations on EUS-guided biliary drainage and the expertise it requires.
- Prospective randomized trial comparing conventional and underwater endoscopic submucosal dissection for superficial colorectal neoplasms. Nagata M et al. Endoscopy, 2025. Earlier randomised evidence from Japan on underwater colorectal ESD.
Comments
New comment